| Survival: | 4.7 months |
| Toxicity Grade: | 5 |
| Treatments: | Chemotherapy |
| Drugs: | Gemzar |
| Country: | United States |
| City/State/Province: | Chicago, Illinois |
| Hospital: | University of Chicago Medical Center |
| Journal: | Link |
| Date: | 2/2001 |
| Description: |
| Patients: This Phase II study involved 17 patients with malignant mesothelioma. Treatment: The treatment consisted of the chemotherapy drug, gemcitabine. Toxicity: Two patients died without documentation of progressive disease and at least one of these deaths was considered related to drug toxicity and disease progression. In addition, grade 3-4 toxicities included hematologic, infection, dyspnea, edema, malaise/fatigue, cerebellar, cardiac dysrhythmia, and hyponatremia. Results: There were no complete or partial responses and the median survival time was 4.7 months. Correspondence: Hedy L. Kindler, MD |